Early Convalescent Plasma Therapy and Mortality Among US Veterans Hospitalized With Nonsevere COVID-19: An Observational Analysis Emulating a Target Trial.

Kelly ChoSarah C KeithlyKatherine E KurganskyArin L Madenci Hanna GerlovinHelen Marucci-WellmanAnnie DoubledayEva R ThomasYojin ParkYuk-Lam HoJonathan D SugimotoKathryn P MooreAlexander C PetersonConstance HoagKalpana GuptaKaren JeansMolly KloteRachel RamoniGrant D HuangJuan P CasasDavid R GagnonMiguel A HernánNicholas L SmithJ Michael Gaziano

Published in: The Journal of infectious diseases (2021)

Our target trial emulation estimated no meaningful differences in 30-day mortality between nonsevere COVID-19 patients treated and untreated with convalescent plasma. Clinical Trials Registration. NCT04545047.

Keyphrases

clinical trial
coronavirus disease
sars cov
phase iii
phase ii
study protocol
cardiovascular events
open label
risk factors
randomized controlled trial
respiratory syndrome coronavirus
coronary artery disease
cardiovascular disease
type diabetes
stem cells
mesenchymal stem cells
data analysis